Clinical trial SOLAR-1 CBYL719C2301
A phase III randomized double-blind, placebo controlled study of alpelisib in combination with fulvestrant for men and postmenopausal women with hormone receptor positive, HER2-negative advanced breast cancer which progressed on or after aromatase inhibitor treatment CBYL719C2301 (SOLAR-1)
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Novartis |
| EudraCT Identifier | 2015-000340-42 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT02437318 |
| Inclusion criteria | Identified PIK3CA status |
| Last update |